These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9730464)

  • 21. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
    Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
    Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population.
    Berger AP; Deibl M; Strasak A; Bektic J; Pelzer A; Steiner H; Spranger R; Fritsche G; Bartsch G; Horninger W
    Urology; 2006 Nov; 68(5):1067-71. PubMed ID: 17095070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.
    Uzzo RG; Pinover WH; Horwitz EM; Parlanti A; Mazzoni S; Raysor S; Mirchandani I; Greenberg RE; Pollack A; Hanks GE; Watkins-Bruner D
    Urology; 2003 Apr; 61(4):754-9. PubMed ID: 12670560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive factors and oncological outcomes of persistently elevated prostate-specific antigen in patients following robot-assisted radical prostatectomy.
    Kumar A; Samavedi S; Mouraviev V; Bates AS; Coelho RF; Rocco B; Patel VR
    J Robot Surg; 2017 Mar; 11(1):37-45. PubMed ID: 27245233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early detection of recurrent prostate cancer with an ultrasensitive chemiluminescent prostate-specific antigen assay.
    Ellis WJ; Vessella RL; Noteboom JL; Lange PH; Wolfert RL; Rittenhouse HG
    Urology; 1997 Oct; 50(4):573-9. PubMed ID: 9338734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL.
    Inman BA; Davies JD; Rangel LJ; Bergstralh EJ; Kwon ED; Blute ML; Karnes RJ; Leibovich BC
    Cancer; 2008 Oct; 113(7):1544-51. PubMed ID: 18680171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
    Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
    Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
    de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
    J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy.
    Richardson TD; Wojno KJ; Liang LW; Giacherio DA; England BG; Henricks WH; Schork A; Oesterling JE
    Urology; 1996 Dec; 48(6A Suppl):40-4. PubMed ID: 8973698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
    Naito S
    Jpn J Clin Oncol; 2005 Jul; 35(7):365-74. PubMed ID: 15976063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
    Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC
    J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
    Patel A; Dorey F; Franklin J; deKernion JB
    J Urol; 1997 Oct; 158(4):1441-5. PubMed ID: 9302139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage.
    Shekarriz B; Upadhyay J; Wood DP; Hinman J; Raasch J; Cummings GD; Grignon D; Littrup PJ
    Urology; 1999 Dec; 54(6):1044-8. PubMed ID: 10604706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases.
    Partin AW; Pearson JD; Landis PK; Carter HB; Pound CR; Clemens JQ; Epstein JI; Walsh PC
    Urology; 1994 May; 43(5):649-59. PubMed ID: 7513108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.